XPC Lys939Gln(A/C)基因多态性与胃癌易感性的Meta分析

doi:10.3760/cma.j.issn.1673-422X.2016.08.009

摘要/Abstract

摘要： 目的探讨着色性干皮病C（XPC）基因939氨基酸位点Lys/Gln多态性与胃癌易感性的关系。方法计算机检索PubMed、Cochrane Library、Elsevier、SpringerVerlag、中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、维普中文科技期刊数据库（VIP）及万方医药期刊全文数据库，检索时间为建库至2015年9月，收集有关XPC Lys939Gln(A/C)基因多态性与胃癌易感性的病例对照研究。由两名评价员按照纳入、排除标准独立筛选文献，进行质量评价。采用STATA 12.0软件进行Meta分析，计算比值比（OR）及95%可信区间（CI）进行关联强度评价，并进行亚组、敏感性分析和发表偏倚的检测。结果本研究共纳入7个病例对照研究，包括2 336例胃癌患者和3 502例健康对照。Meta分析结果显示，与等位基因A比较，等位基因C可增加胃癌的风险（OR=1.09，95%CI为1.01~1.18，Z=2.12，P=0.034）；与基因型AA相比，纯合子模型（CC）和显性模型（CC+AC）基因型可增加罹患胃癌风险（CC vs.AA：OR=1.19，95%CI为1.00~1.42，Z=2.00, P=0.046；CC+AC vs.AA：OR=1.12，95%CI为1.00~1.25，Z=2.03，P=0.042）。对研究人群和对照来源进行亚组分析结果显示，在亚洲人群和社区来源的对照中，XPC Lys939Gln(A/C)基因多态性与胃癌风险有关。亚洲人群中，C vs.A: OR=1.10，95%CI为1.01~1.20，Z=2.28，P=0.023；CC vs.AA：OR=1.21，95%CI为1.01~1.46，Z=2.02，P=0.043；CC+AC vs.AA：OR=1.13，95%CI为1.01~1.27，Z=2.11，P=0.035。社区来源的对照组中，C vs.A：OR=1.11，95%CI为1.01~1.21，Z=2.25，P=0.024；CC vs.AA：OR=1.23，95%CI为1.02~1.50，Z=2.12，P=0.034。结论 XPC Lys939Gln(A/C)基因多态性可能与罹患胃癌的易感性有关。等位基因C、基因型CC和CC+AC可能增加胃癌的风险。

关键词: 胃肿瘤, 多态现象, 遗传, 多态性, 单核苷酸, Meta分析, 着色性干皮病C

Abstract: Objective To explore the association between Xeroderma pigmentosum complementation C group (XPC) Lys939Gln (A/C) gene polymorphism and the susceptibility of gastric cancer. Methods By searching PubMed, Cochrane Library, Elsevier, SpringerVerlag, China National Knowledge Infrastructure, Chinese Biomedical Literature Data, VIP Database and Wanfang Database, all eligible casecontrol studies published up to September 2015 were selected and the quality of each article was valuated by two reviewers independently according to the inclusion and exclusion criteria. Meta-analysis was performed by using STATA 12.0 software. Odds ratio (OR) and 95% confidence interval (CI) were calculated. The text was estimated for the subgroup analysis, sensitivity analysis and publication bias test. Results A total of 7 casecontrol studies were included, including 2 336 cases with gastric cancer and 3 502 controls. The Metaanalysis showed that compared with the allele A, the allele C increased the risk of gastric cancer (OR=1.09, 95%CI: 1.01-1.18, Z=2.12, P=0.034); compared to the genotype AA, the homozygous model (CC) and dominant model (CC+AC) also increased the risk of gastric cancer (CC vs.AA: OR=1.19, 95%CI: 1.00-1.42, Z=2.00, P=0.046; CC+AC vs.AA: OR=1.12, 95%CI: 1.00-1.25, Z=2.03, P=0.042). The Meta-analysis showed the statistical significance between XPC Lys939Gln (A/C) gene polymorphism and the gastric cancer risk in subgroup of Asian people (C vs.A: OR=1.10, 95%CI: 1.01-1.20, Z=2.28, P=0.023; CC vs.AA: OR=1.21, 95%CI: 1.01-1.46, Z=2.02, P=0.043; CC+AC vs.AA: OR=1.13, 95%CI: 1.01-1.27, Z=2.11, P=0.035) and the source of community in the control group (C vs.A: OR=1.11, 95%CI: 1.01-1.21, Z=2.25, P=0.024; CC vs.AA: OR=1.23, 95%CI: 1.02-1.50, Z=2.12, P=0.034). Conclusion XPC Lys939Gln(A/C) gene polymorphism may be associated with the susceptibility of gastric cancer, and genotype CC, CC+AC and allele C can increase the risk of gastric cancer.

Key words: Stomach neoplasms, Polymorphism, genetic, Polymorphism, single nucleotide, Meta-analysis, Xeroderma pigmentosum complementation C group

崔静,谭辉,姜雷,袁文臻,关泉林. XPC Lys939Gln(A/C)基因多态性与胃癌易感性的Meta分析[J]. 国际肿瘤学杂志, 2016, 43(8): 597-602.

Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC Lys939Gln(A/C) gene polymorphism and the susceptibility of gastric cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(8): 597-602.

参考文献

［1］ Fock KM. Review article: the epidemiology and prevention of gastric cancer［J］. Aliment Pharmacol Ther, 2014, 40(3): 250-260. DOI: 10.1111/apt.12814. ［2］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［3］邹文斌, 吴浩, 蔡全才，等. 胃癌危险因素研究进展［J］. 中国实用内科杂志, 2014, 34(4): 415-420. ［4］吴雪铭, 马韵, 龙喜带. DNA修复基因XPC研究进展［J］. 右江民族医学院学报, 2009, 31(5): 876-878. DOI: 10.3969/j.issn.1001-.2009.05.088. ［5］李龙嫚, 余红平. XPC、XPG基因单核苷酸多态性与肿瘤遗传易感性关系的研究进展［J］. 医学综述, 2010, 16(6): 801-804. ［6］ Thoma BS, Vasquez KM. Critical DNA damage recognition functions of XPC-hHR23B and XPA-RPA in nucleotide excision repair［J］. Mol Carcinog, 2003, 38(1): 1-13. ［7］ Sugasawa K, Ng JM, Masutani C, et al. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair［J］. Mol Cell, 1998, 2(2): 223-232. ［8］ Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and singlestrand breaks in DNA［J］. Carcinogenesis, 2004, 25(5): 757-763. ［9］陈泽鑫, 刘慧, 潘益峰, 等. 试验性和观察性研究相关医学文献质量评价方法［J］. 中国循证医学杂志, 2011, 11(11): 1229-1236. ［10］李丹萍, 侯慧, 徐昌青, 等. xpc基因多态性与胃癌发生风险的关系［J］. 山东医药, 2014, 54(13): 2426. DOI: 10.3969/j.issn.1002-266X.2014.13.009. ［11］贺静. 核苷酸剪切修复基因单核苷酸多态性与胃癌遗传易感性的分子流行病学研究［D］. 上海: 复旦大学, 2013. ［12］ Long XD, Ma Y, Huang YZ, et al. Genetic polymorphisms in DNA repair genes XPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China［J］. Mol Carcinog, 2010, 49(6): 611-618. DOI: 10.1002/mc.20630. ［13］ Ye W, Kumar R, Bacova G, et al. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a populationbased casecontrol study in Sweden［J］. Carcinogenesis, 2006, 27(9): 1835-1841. ［14］ Engin A, Karahalil B, Engin A, et al. DNA repair enzyme polymorphisms and oxidative stress in a Turkish population with gastric carcinoma［J］. Mol Biol Rep, 2011, 38(8): 5379-5386. DOI: 10.1007/s11033-011-0690-9. ［15］ Dong Z, Guo W, Zhou R, et al. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China［J］. J Clin Gastroenterol, 2008, 42(8): 910-915. DOI: 10.1097/MCG.0b013e3180f6262c. ［16］郭剑波. DNA修复基因XPC多态性及单体型与胃癌遗传易感性的关系［D］. 辽宁: 中国医科大学, 2012. ［17］ Ang TL, Fock KM. Clinical epidemiology of gastric cancer［J］. Singapore Med J, 2014, 55(12): 621-628. ［18］ Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review［J］. J Natl Cancer Inst, 2000, 92(11): 874-897. ［19］ He J, Shi TY, Zhu ML, et al. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis［J］. Int J Cancer, 2013, 133(8): 1765-1775. DOI: 10.1002/ijc.28089. ［20］ Janicijevi′c A, Sugasawa K, Shimizu Y, et al. DNA bending by the human damage recognition complex XPC-HR23B［J］. DNA Repair (Amst), 2003, 2(3): 325-336. ［21］ Tapias A, Auriol J, Forget D, et al. Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors［J］. J Biol Chem, 2004, 279(18): 19074-19083. ［22］袁芃, 缪小平, 张雪梅, 等. 核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系［J］. 癌症, 2005, 24(12): 1510-1513. ［23］ Francisco G, Menezes PR, Eluf-Neto J, et al. XPC polymorphisms play a role in tissue-specific carcinogenesis: a metaanalysis［J］. Eur J Hum Genet, 2008, 16(6): 724-734. DOI: 10.1038/ejhg.2008.6. ［24］ Blankenburg S, K-nig IR, Moessner R, et al. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a casecontrol study［J］. Carcinogenesis, 2005, 26(6): 1085-1090. ［25］郭炜, 周荣秒, 李琰, 等. XPC基因多态性与食管鳞状细胞癌、贲门腺癌的发病风险［J］. 肿瘤防治研究, 2007, 34(3): 209-213. ［26］ Jiang X, Zhou LT, Zhang SC, et al. XPC polymorphism increases risk of digestive system cancers: current evidence from a metaanalysis［J］. Chin J Cancer Res, 2012, 24(3): 181-189. DOI: 10.1007/s11670-012-0181-0. ［27］ Peng Q, Chen Z, Lu Y, et al. Current evidences on XPC polymorphisms and gastric cancer susceptibility: a meta-analysis［J］. Diagn Pathol, 2014, 9: 96. DOI: 10.1186/1746-1596-9-96.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[10]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[11]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[12]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[13]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[14]	陈志明, 陈俊杰, 李李, 丁倩, 韩钰楠, 赵洪瑜. 全外显子组测序筛查食管鳞状细胞癌放疗抵抗相关基因研究[J]. 国际肿瘤学杂志, 2023, 50(10): 592-599.
[15]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.